CHAARTED

In metastatic hormone-sensitive prostate cancer, does adding docetaxel to ADT improve survival?

What changes for patients?

Updated follow-up showed median OS 57.6 vs 47.2 months, a 10.4-month median difference, with HR 0.72. Benefit was greatest in high-volume disease. NNT is not derived from median survival because a reliable fixed-time absolute mortality estimate is not the appropriate basis here.

NNT: Not appropriately calculable from median survival

Median survival is shown as reported; the 10.4-month difference is not a fixed-time absolute risk reduction and should not be converted into an NNT.

Docetaxel treatment toxicity

NNH: Not quantifiable from the selected primary endpoint; febrile neutropenia and other chemotherapy toxicity reported in text

HR: 0.72

95% CI 0.59–0.89

Docetaxel added to ADT improved survival most clearly in high-volume mHSPC; the absolute value depends on disease burden, fitness and the modern choice of ARPI doublets or triplets.

• Sweeney CJ, et al. N Engl J Med. 2015;373:737–746.
• Kyriakopoulos CE, et al. J Clin Oncol. 2018;36:1080–1087.
• Primary publication / source
• Primary publication / source